Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend

Bulletin Express08-13 17:09

Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.

The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).

The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146232852?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146232852","market":"hk","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical Schedules 25 Aug Board Meeting to Approve 1H 2026 Results and Consider Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 17:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.</p>\n<p>The meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).</p>\n<p>The announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1146232852","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146232852","pubTimestamp":1786612181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"广州英诺健制药定于 8 月 25 日召开董事会会议，批准 2026 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened a board meeting for 25 August 2026. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and deliberate on a potential interim dividend.\nThe meeting notice, signed by Chairman Dr. Wang Qinghua, specifies that all agenda items will focus on financial performance evaluation and dividend recommendations. The Board currently comprises four executive directors (Dr. Wang Qinghua, Jiang Fan, Xu Wenjie and Huang Bing), two non-executive directors (Ho Kyung Shik and Heng Lei) and three independent non-executive directors (Tao Wuping, Dr. Song Ruilin and Chan Heung Wing Anthony).\nThe announcement was released from Shanghai on 13 August 2026. Guangzhou Innogen Pharmaceutical’s shares are listed on the Stock Exchange of Hong Kong under the name INNOGEN-B.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146232852","isCrawlerRequest":true}